This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lübbe, A. S. Articles by Huhn, D. Search for Related Content PubMed PubMed Citation Articles by Lübbe, A. S. Articles by Huhn, D.

Clinical Experiences with Magnetic Drug Targeting: A Phase I Study with 4'-Epidoxorubicin in 14 Patients with Advanced Solid Tumors¹

Departments of Medicine (Hematology and Oncology) [A. S. L., C. B., H. R., F. S., W. H., D. H.], Traumatology and Plastic Surgery [N. H.], Radiology [B. S., A-J. L.], and Pharmacy [D. O.], Virchow Medical School, Humboldt-Universität zu Berlin, Augustenburger Platz I, 13353 Berlin; Departments of Medical Oncology and Tumor Immunology [P. R., B. D.], Medical Oncology and Molecular Biology [F. H., R. G.], and Surgical Oncology [P. H.], Robert-Rössle-Klinik, Virchow Medical School, Humboldt-Universität zu Berlin, Lindenberger Weg 80. 13125 Berlin: Department of Medical Oncology, Charite Medical School, Humboldt-Universität zu Berlin, Schumannstraße 20/21. 10117 Berlin [K. P., M. M.]; and Department of Pharmacology and Toxicology, Charite Medical School, Humboldt-Universität zu Berlin, Dorotheenstraße 94. 10117 Berlin [R. S.], Germany

Anticancer drugs reversibly bound to magnetic fluids (ferrofluids) could be concentrated in locally advanced tumors by magnetic fields that are arranged at the tumor surface outside of the organism. If certain requirements are met, systemic toxicity might be minimized, and local tumor efficacy might be increased. We have conducted a Phase I clinical trial using this approach in patients with advanced and unsuccessfully pretreated cancers or sarcomas. Nine such patients received two treatment courses, 3 patients received one course, and 2 patients received three courses of magnetic drug targeting consisting of the infusion of epirubicin in increasing doses (from 5 to 100 mg/m²) that had been chemically bound to a magnetic fluid and the application of magnetic fields to the tumors for 60–120 min. In 2 of 14 patients, the same dose of epirubicin not bound to a magnetic fluid was administered systemically 3 weeks after drug targeting for intraindividual comparisons. Magnetic drug targeting with epirubicin was well tolerated. In one case, a planned second treatment was withdrawn, because of an episode of chills 130 min after infusion of the magentic drug. Two patients received a third treatment because of good responses after the first two therapies. Based on magnetic resonance tomographic techniques, pharmacokinetics, and the histological detection of magnetites, it was shown that the ferrofluid could be successfully directed to the tumors in about one-half of the patients. Organ toxicity did not increase with the treatment, but epirubicin-associated toxicity appeared at doses greater than 50 mg/m². Although treatment with magnetic drug targeting seems safe, improvements are necessary to make it more effective and independent of patient- or disease-related problems. A study design to compare conventional treatments with the new treatment form within one patient seems crucial to eliminate interindividual differences.

¹ This work was made possible by the generous support of Pharmacia.

² To whom requests for reprints should be addressed, at Cecilien-Klinik, Cecilienallee 6–8, 33175 Bad Lippspringe, Germany.

Received 2/21/96. Accepted 8/15/96.

This article has been cited by other articles:

				A. Durdureanu-Angheluta, I. Stoica, M. Pinteala, L. Pricop, F. Doroftei, V. Harabagiu, B. C. Simionescu, and H. Chiriac Glycidoxypropylsilane-functionalized Magnetite as Precursor for Polymer-covered Core-shell Magnetic Particles High Performance Polymers, October 1, 2009; 21(5): 548 - 561. [Abstract] [PDF]

				M. Chorny, B. Polyak, I. S. Alferiev, K. Walsh, G. Friedman, and R. J. Levy Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles FASEB J, August 1, 2007; 21(10): 2510 - 2519. [Abstract] [Full Text] [PDF]

				C. Riviere, M.-S. Martina, Y. Tomita, C. Wilhelm, A. Tran Dinh, C. Menager, E. Pinard, S. Lesieur, F. Gazeau, and J. Seylaz Magnetic Targeting of Nanometric Magnetic Fluid loaded Liposomes to Specific Brain Intravascular Areas: A Dynamic Imaging Study in Mice Radiology, August 1, 2007; 244(2): 439 - 448. [Abstract] [Full Text] [PDF]

				J.-P. Fortin-Ripoche, M. S. Martina, F. Gazeau, C. Menager, C. Wilhelm, J.-C. Bacri, S. Lesieur, and O. Clement Magnetic Targeting of Magnetoliposomes to Solid Tumors with MR Imaging Monitoring in Mice: Feasibility Radiology, May 1, 2006; 239(2): 415 - 424. [Abstract] [Full Text] [PDF]

				I. Hilger, W. Andra, R. Hergt, R. Hiergeist, H. Schubert, and W. A. Kaiser Electromagnetic Heating of Breast Tumors in Interventional Radiology: In Vitro and in Vivo Studies in Human Cadavers and Mice Radiology, February 1, 2001; 218(2): 570 - 575. [Abstract] [Full Text]

				C. Alexiou, W. Arnold, R. J. Klein, F. G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. Wagenpfeil, and A. S. Lubbe Locoregional Cancer Treatment with Magnetic Drug Targeting Cancer Res., December 1, 2000; 60(23): 6641 - 6648. [Abstract] [Full Text]

				F. A. De Wolf and G. M. Brett Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands Pharmacol. Rev., June 1, 2000; 52(2): 207 - 236. [Abstract] [Full Text] [PDF]